Cybin Inc.

Cybin Inc.

Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights

- Company to host conference call at 4:30pm EST today –TORONTO, November 15, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today reported unaudited financial results for its second quarter ended September 30... Read More...

Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021

TORONTO, November 09, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM" today announced that it will report financial results for its second quarter of fiscal 2021 ended September 30, 2021 on Monday, November 15,... Read More...

Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health

Comparative CYB003 pre-clinical data on the Company’s deuterated psilocybin analog may have wide-reaching implications for the treatment of Major Depressive Disorder ("MDD") and Alcohol Use Disorder ("AUD") with less patient variability, faster onset of action, shorter duration of effect and improved brain penetrationTORONTO, November 08,... Read More...

Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development

Promotion of Certain Members of Management Team and Engagement with a Capital Markets Communications FirmTORONTO, October 01, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce: the addition of Dr. Ami... Read More...

Cybin Announces Election of Theresa Firestone as Director, Results of Shareholders’ Meeting and Adoption of Shareholder Rights Plan

TORONTO, August 16, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Theresa Firestone has been elected to its board of directors at the Company’s annual and special meeting of shareholders held... Read More...

Cybin to Commence Trading on the NYSE American on August 5

TORONTO, August 04, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its common shares will open for trading on the NYSE American LLC stock exchange ("NYSE American") on August 5, 2021, under the symbol "CYBN... Read More...

Cybin Announces Closing of Overnight Marketed Public Offering of Common Shares and Exercise of Over-Allotment Option

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, August 03, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB: CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has closed its previously announced over... Read More...

Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, July 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, announced today the pricing of its previously announced overnight market... Read More...

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

TORONTO, June 28, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the "Company"), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved certain earn-out milestones for the period ... Read More...

Cybin Announces CDN$20 Million Bought Deal Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/TORONTO, Jan. 18, 2021 - Cybin Inc. (NEO: CYBN) ("Cybin" or the "Company"), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. ("... Read More...

Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition

Cybin Inc. (NEO:CYBN) ("Cybin" or the "Company"), a life sciences company focused on psychedelic therapeutics, is pleased to announce that Adelia Therapeutics Inc. ("Adelia"), a wholly-controlled subsidiary of Cybin, has achieved the earn-out milestones for the period commencing November 15, 2020, as contemplated by the terms of a contrib... Read More...

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

HIGHLIGHTSUsing Kernel’s technology, Cybin will be able to quantify brain activity in real time during psychedelic experiences. The absence of this data has been a limitation in the progression of new molecules targeting neurological disorders.Kernel’s technology opens new frontier in psychedelic therapeutics by acquiring longitudinal bra... Read More...

CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth

Cybin to host conference call today, December 7, 2020, at 5:00 p.m. ETTransaction adds extensive intellectual property portfolio and product pipeline to potentially diversify Cybin’s programs and includes multiple additional indications.Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic ... Read More...